article thumbnail

In vivo mitral valve repair for the transplanted donor heart in orthotopic heart transplantation

Journal of Cardiothoracic Surgery

A 53-year-old woman with the dilated phase of hypertrophic cardiomyopathy underwent orthotopic heart transplantation. The donor heart was evaluated as normal preoperatively without mitral regurgitation or the.

article thumbnail

Arrhythmias in children undergoing orthotopic heart transplantation

Frontiers in Cardiovascular Medicine

Introduction Heart transplantation (HT) is the only treatment option in children with heart failure secondary to cardiomyopathies and non-reparable congenital heart diseases. Results We identified 27 children (66.7% On a median follow-up of 35.07 months (IQR: 13.13–111.87),

article thumbnail

Phenotypes in Arrhythmogenic Cardiomyopathy

All About Cardiovascular System and Disorders

Arrhythmogenic Cardiomyopathy was better known as Arrhythmogenic Right Ventricular Dysplasia or ARVD and sometimes as Arrhythmogenic Right Ventricular Cardiomyopathy or ARVC earlier. A study published in JACC has compared the phenotypic expression and clinical outcomes in patients with arrhythmogenic cardiomyopathy [2].

article thumbnail

Thirty Five Year Follow up of Three Generations of a Family with LMNA Cardiomyopathy

HeartRhythm

The clinical syndrome of combined cardiomyopathy and skeletal myopathy described in 2001 (1) was one of the initial descriptions of LMNA cardiomyopathy, a genetic variant. In 2001, genetic testing failed to detect the abnormality in this family.

article thumbnail

Progressive Left Ventricular Remodeling for Predicting Mortality in Children With Dilated Cardiomyopathy: The Pediatric Cardiomyopathy Registry

Journal of the American Heart Association

Journal of the American Heart Association, Ahead of Print. BackgroundPediatric dilated cardiomyopathy often leads to death or cardiac transplantation. The risk for death or cardiac transplantation up to 7 years later was lower when LVFS was improved at 1 year (hazard ratio [HR], 0.83;P=0.004) P<0.001).ConclusionsProgressive

article thumbnail

One step closer to the new frontiers of healthcare for cardiomyopathy patients

Heart BMJ

There were great advances in the treatment of heart failure (HF) over the past decades, characterised by the inclusion of ARNI and SGLT2 inhibitors in the latest guidelines. 1 The increasing repertoire of treatments makes it even more important to select those patients who will benefit the most from these therapies.

article thumbnail

Association of Plasma Creatinine Phosphokinase Elevation and a History of Idiopathic Cardiomyopathy in Heart Transplant Recipients

The American Journal of Cardiology

Publication date: Available online 16 December 2023 Source: The American Journal of Cardiology Author(s): Pierre Ambrosi, Alberto Riberi, Shahram Attarian, Karine Nguyen, Régis Guieu, Gilbert Habib